<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20040820152618+02'00'</creation_date><modification_date>D:20040820152631+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-04-283_h_dec_0.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communities</p><p>brussels, 11-viii-2004 c(2004) 3160 
 not for publication</p></section><section><header>commission decision of 11-viii-2004 
 granting marketing authorisation for the medicinal product for human use 
 &quot;ariclaim - duloxetine hydrochloride&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>only the german text is authentic</p></section><section><header>en  
   en</header></section><section><header>en  
   en</header></section><section><header>commission decision of 11-viii-2004 
 granting marketing authorisation for the medicinal product for human use 
 &quot;ariclaim - duloxetine hydrochloride&quot; under council regulation (eec) no 2309/93 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and in particular article 10(2) thereof, 
 having regard to the application submitted by boehringer ingelheim international 
 gmbh, on 26 june 2003, under article 4(1) of regulation (eec) no 2309/93, 
 concerning the medicinal product, 
 having regard to the opinion of the european agency for the evaluation of medicinal 
 products, formulated by the committee for proprietary medicinal products on 24 march 
 2004, 
 whereas: 
 (1)</p><p>the medicinal product &quot;ariclaim - duloxetine hydrochloride&quot; complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 3 as amended by directive 2002/98/ec4 and by directive 2003/63/ec
 5. (2)</p><p>it is therefore appropriate to authorise its placing on the market. 
 (3)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 1 oj l 214, 24. 8. 1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 311, 28.11.2001, p. 67. 4 oj l 33, 8.2.2003, p. 30. 5 oj l 159, 27.6.2003, p. 46.</p></section><section><header>en  
   en</header><p>has adopted this decision: article 1 the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product, &quot;ariclaim - duloxetine 
 hydrochloride&quot; whose characteristics are summarized in annex i hereto. this medicinal 
 product shall be entered in the community register of medicinal products under the 
 numbers: 
 eu/1/04/283/001 
 20 
 mg-hard 
 gastro-resistant 
 capsules-oral 
 use-blisters 
 (pvc/pe/pctfe/alu)-56 capsules 
 eu/1/04/283/002 
 40 
 mg-hard 
 gastro-resistant 
 capsules-oral 
 use-blisters 
 (pvc/pe/pctfe/alu)-28 capsules 
 eu/1/04/283/003 
 40 
 mg-hard 
 gastro-resistant 
 capsules-oral 
 use-blisters 
 (pvc/pe/pctfe/alu)-56 capsules 
 eu/1/04/283/004 
 40 
 mg-hard 
 gastro-resistant 
 capsules-oral 
 use-blisters 
 (pvc/pe/pctfe/alu)-98 capsules 
 eu/1/04/283/005 
 40 
 mg-hard 
 gastro-resistant 
 capsules-oral 
 use-blisters 
 (pvc/pe/pctfe/alu)-140 capsules 
 eu/1/04/283/006 
 40 
 mg-hard 
 gastro-resistant 
 capsules-oral 
 use-blisters 
 (pvc/pe/pctfe/alu)-2 x 98 capsules 
 article 2 the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and importation, control and issue referred to in annex ii. 
 article 3 the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii. 
 article 4 the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in 
 article 13(1) of regulation (eec) no 2309/93.</p></section><section><header>en  
   en</header><p>article 5 this decision is addressed to boehringer ingelheim international gmbh, binger strasse 173, d-55216 ingelheim am rhein, deutschland. 
 done at brussels, 11-viii-2004 
 for the commission olli rehn</p><p>
 member of the commission</p></section></body></xml>